By using specific inhibitors toward LPCAT3 ((R)-HTS-3) or ACSL4 (rosiglitazone) in enzymatic activity assays, we found that the substrate conversion rate of LPCAT3 did not exhibit differences between TRCs and bulk tumor cells, whereas ACSL4 catalytic activity was significantly decreased in TRCs (Extended Data Fig. 3b,c and Supplementary Fig. 3a–c). Here, LPCAT3 is linked to neoplasm.